Rates, predictors, and consequences of remission from chronic migraine to episodic migraine

Neurology

Volumn 76, Issue 8, 2011, Pages 711-718

  Manack, A ^a   Buse, D C ^b   Serrano, D ^c,d   Turkel, C C ^a   Lipton, R B ^b  

^a ALLERGAN INC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VEDANTA RESEARCH   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BARBITURIC ACID DERIVATIVE; CAFFEINE; ERGOTAMINE DERIVATIVE; EXCEDRIN; ISOMETHEPTENE MUCATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; TRIPTAN DERIVATIVE;

ADULT; AGED; ALLODYNIA; ARTICLE; COMORBIDITY; EPISODIC MIGRAINE; FEMALE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; REMISSION; STRUCTURED QUESTIONNAIRE; TRANSFORMED MIGRAINE;

EID: 79952026321     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820d8af2     Document Type: Article

References (24)

1. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(suppl 1):9-160.
2. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-746.
3. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157-1168.
4. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-495. (Pubitemid 351502554)
5. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009;72(5 suppl):S3-S7.
6. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349. (Pubitemid 46184209)
7. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 1996;16:231-238. (Pubitemid 26189248)
8. Blumenfeld AM, Varon SF, Buse DC, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia Epub 2010 Sep 2.
9. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613. (Pubitemid 32823891)
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 2000.
11. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008;63:148-158. (Pubitemid 351355293)
12. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999;149:981-983. (Pubitemid 29246861)
13. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D'Amico D. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 2004;25(suppl 3):S105-S107. (Pubitemid 41461969)
14. Lipton RB, Varon SF, Grosberg B, et al. Onabotulinum-toxinA treatment improves health-related quality of life and reduces the impact of chronic migraine: results from the double-blind phase of the PREEMPT clinical program. Poster presented at the 14th International Headache Congress, September 10-13, 2009, Philadelphia, PA.
15. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003;23:441-450. (Pubitemid 36776060)
16. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449-454.
17. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42:36-42. (Pubitemid 26030543)
18. Hurst BC, Patrick DL. Quality of life improvement in responders to long-term treatment with Zomig. Presented at the 40th Annual Scientific Meeting of the American Association of the Study of Headache, June 26-28, 1998, San Francisco, CA.
19. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010;81:428-432.
20. Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 1993;27:211-221. (Pubitemid 23234204)
21. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders-a national population-based study. Headache 2008;48:501-516. (Pubitemid 351464683)
22. Lantéri-Minet M, Radat F, Chautard MH, Lucas C. Anxiety and depression associated with migraine: influence on migraine subjects' disability and quality of life, and acute migraine management. Pain 2005;118:319-326. (Pubitemid 41752989)
23. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-363. (Pubitemid 46426410)
24. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87-96. (Pubitemid 28155226)